Vitrolife AB: Interim report Q2, 2025: Strong performance across Consumables

Rhea-AI Summary

Vitrolife AB (VTRLY) reported Q2 2025 financial results showing mixed performance. Sales reached SEK 871 million, reflecting flat growth in local currencies and a 7% decrease in SEK due to an 8% negative currency impact. The company achieved 3% organic growth in local currencies excluding discontinued business.

Regional performance varied with EMEA showing -3% growth (5% excluding discontinued business), Americas growing 5%, and APAC remaining flat. The Consumables segment demonstrated strong performance with 9% growth excluding discontinued business, while Technologies declined 6% and Genetics grew 3%. The company's EBITDA margin decreased to 27.8% from 34.7%, with net income at SEK 100 million and earnings per share of SEK 0.74.

[ "Consumables segment showed strong 9% growth excluding discontinued business", "Americas region achieved 5% sales growth", "3% organic growth in local currencies excluding discontinued business", "Genetics segment maintained positive growth at 3% excluding discontinued business", "Operating cash flow remained positive at SEK 151 million", "Strategic acquisition of leading stake in AutoIVF" ]

Positive

• None.

Negative

• Overall sales decreased 7% in SEK due to significant currency impact
• EBITDA margin declined significantly to 27.8% from 34.7%
• Gross margin decreased to 58.0% from 59.9%
• Technologies segment declined 6%
• Net income decreased to SEK 100 million from SEK 143 million
• APAC region showed no growth

GOTHENBURG, Sweden, July 17, 2025 /PRNewswire/ --

Second quarter 

• Sales of SEK 871 (941) million, a flat growth in local currencies and a 7% decrease in SEK, due to a significant currency impact of -8%. Organic growth in local currencies excluding discontinued business was 3%.
• Sales per region, in local currencies was -3% in EMEA, +5% excluding discontinued business, +5% in Americas and 0% in APAC.
• Sales per product group, in local currencies excluding discontinued business was +9% in Consumables, -6% in Technologies and +3% in Genetics.
• Sales per product group, in local currencies was +5% in Consumables, -8% in Technologies and 0% in Genetics.
• Gross margin decreased to 58.0% (59.9) also negatively impacted by currency.
• Earnings before depreciation and amortisation (EBITDA) decreased to SEK 243 (327) million, resulting in an EBITDA margin of 27.8% (34.7), significantly impacted by negative currency effect.
• Operating cash flow amounted to SEK 151 million (236).
• Net income was SEK 100 (143) million, resulting in earnings per share of SEK 0.74 (1.06).
• Vitrolife AB (publ) acquired a leading stake in AutoIVF.

First half year

• Sales of SEK 1,714 (1,782) million, a flat growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -4%. Organic growth in local currencies excluding discontinued business was 3%.
• Sales per region, in local currencies was +2% in EMEA, +10% excluding discontinued business, +7% in Americas and -8% in APAC.
• Sales per product group, in local currencies excluding discontinued business was +7% in Consumables, -6% in Technologies and +4% in Genetics.
• Sales per product group, in local currencies was +4% in Consumables, -7% in Technologies and +1% in Genetics.
• Gross margin decreased to 57.7% (58.6) also negatively impacted by currency.
• Earnings before depreciation and amortisation (EBITDA) decreased to SEK 500 (600) million, resulting in an EBITDA margin of 29.2% (33.6), significantly impacted by negative currency effect.
• Operating cash flow amounted to SEK 220 million (434).
• Net income was SEK 199 (258) million, resulting in earnings per share of SEK 1.48 (1.91).

Gothenburg, July 17, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2025 08:00 CET.

Contact:
Amelie Wilson,
Investor Relations,
External Corporate Communications and Executive Support,
awilson@vitrolife.com 

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q2--2025--strong-performance-across-consumables,c4207968

The following files are available for download:

https://mb.cision.com/Main/1031/4207968/3582776.pdf

Interim report Q2, 2025

 

 

 

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-interim-report-q2-2025-strong-performance-across-consumables-302507696.html

SOURCE Vitrolife AB

FAQ

What were Vitrolife's (VTRLY) Q2 2025 earnings results?

Vitrolife reported Q2 2025 sales of SEK 871 million, with net income of SEK 100 million and earnings per share of SEK 0.74. The company achieved flat growth in local currencies with a 3% organic growth excluding discontinued business.

How did Vitrolife's different segments perform in Q2 2025?

In Q2 2025, Consumables showed the strongest performance with 9% growth excluding discontinued business, while Technologies declined by 6% and Genetics grew by 3%.

What was Vitrolife's regional sales performance in Q2 2025?

Regional sales performance in local currencies showed -3% in EMEA (5% excluding discontinued business), +5% growth in Americas, and 0% growth in APAC.

How did currency impact affect Vitrolife's Q2 2025 results?

Currency impact significantly affected Vitrolife's results with a negative 8% effect, leading to a 7% decrease in SEK-denominated sales and impacting both gross margin and EBITDA margin negatively.

What was Vitrolife's EBITDA margin in Q2 2025?

Vitrolife's EBITDA margin in Q2 2025 was 27.8%, down from 34.7% in the previous year, primarily due to significant negative currency effects.